Fetroja, Fetcroja(cefiderocol)
Fetcroja, Fetroja (cefiderocol) is a small molecule pharmaceutical. Cefiderocol was first approved as Fetroja on 2019-11-14. It is used to treat bacterial infections, pyelonephritis, and urinary tract infections in the USA. It has been approved in Europe to treat gram-negative bacterial infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Fetroja
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fetroja | New Drug Application | 2025-05-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| urinary tract infections | EFO_0003103 | D014552 | N39.0 |
| bacterial infections | — | D001424 | A49 |
| pyelonephritis | EFO_1001141 | D011704 | N10-N16 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CEFIDEROCOL SULFATE TOSYLATE, FETROJA, SHIONOGI INC | |||
| 2029-11-14 | GAIN | ||
| 2024-11-14 | NCE | ||
HCPCS
Code | Description |
|---|---|
| J0699 | Injection, cefiderocol, 10 mg |
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 5 | 1 | 1 | 5 | 12 |
| Communicable diseases | D003141 | — | — | — | 4 | 1 | 1 | 5 | 11 |
| Bacterial infections | D001424 | — | A49 | 1 | 3 | — | 2 | 2 | 8 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | 2 | 2 | 2 | — | 7 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | 1 | 2 | 1 | 1 | — | 5 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | 1 | 1 | — | 2 | — | 4 |
| Multiple drug resistance | D018432 | — | — | — | — | — | 1 | 1 | 2 |
| Fibrosis | D005355 | — | — | — | — | — | 1 | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | 1 | — | 1 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 3 | 1 | — | — | 4 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | 1 | 2 | — | — | 3 |
| Healthcare-associated pneumonia | D000077299 | — | — | — | 1 | 2 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gram-negative bacterial infections | D016905 | — | — | — | 3 | — | — | 3 | 6 |
| Intraabdominal infections | D059413 | — | — | — | 1 | — | — | — | 1 |
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | — | 1 | 1 |
| Acute lung injury | D055371 | EFO_0004610 | — | — | — | — | — | 1 | 1 |
| Cross infection | D003428 | — | — | — | — | — | — | 1 | 1 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cefiderocol |
| INN | cefiderocol |
| Description | Cefiderocol, sold under the brand name Fetroja among others, is an antibiotic used to treat complicated urinary tract infections when no other options are available. It is indicated for the treatment of multi-drug-resistant Gram-negative bacteria including Pseudomonas aeruginosa. It is given by injection into a vein.
|
| Classification | Small molecule |
| Drug class | cephalosporins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(CCNC(=O)c4ccc(O)c(O)c4Cl)CCCC3)CS[C@H]12)c1csc(N)n1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 1225208-94-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3989974 |
| ChEBI ID | — |
| PubChem CID | 77843966 |
| DrugBank | DB14879 |
| UNII ID | SZ34OMG6E8 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,908 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
492 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use